Acadian Asset Management
EVOK

Acadian Asset Management’s Evoke Pharma EVOK Stock Holding History

Acadian Asset Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-43
Closed -$22K – 2228
2020
Q2 		$22K Buy
+43
New +$12K ﹤0.01% 2113
2019
Q3 		– Sell
-49
Closed -$4K – 1914
2019
Q2 		$4K Sell
49
-244
-83% -$24.2K ﹤0.01% 1695
2019
Q1 		$63K Buy
+293
New +$100K ﹤0.01% 1622

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WA
Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return

Acadian Asset Management's EVOK Position: Q3 2020 in Review

Acadian Asset Management sold out of Evoke Pharma (EVOK) in Q3 2020, closing a stake of 43 shares — an estimated $22K sold.

Acadian Asset Management first reported a position in EVOK in Q1 2019 and held it in 3 quarters. The position peaked at $63K in Q1 2019. 25 funds tracked by Wall St. Rank hold EVOK as of Q3 2020.

  • Acadian Asset Management reported no remaining Evoke Pharma position as of Q3 2020 after selling out during the quarter.
  • Acadian Asset Management sold 43 Evoke Pharma shares in Q3 2020, an estimated $22K.
  • Acadian Asset Management first reported a position in Evoke Pharma in Q1 2019 and held it in 3 quarters.
  • Acadian Asset Management's Evoke Pharma position peaked at $63K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2020.

Based on Acadian Asset Management's 13F filing for Q3 2020, filed 9 Nov 2020.